mFLUSIVA Moderna Australia Pty Ltd
Product name
mFLUSIVA
Sponsor
Accepted date
Feb-2026
Active ingredients
influenza virus haemagglutinin mRNA
Proposed indication
mFLUSIVA is a vaccine proposed for active immunisation for the prevention of influenza disease in individuals 50 years of age and older.
Application type
A (new medicine)
Publication date
Feb-2026